Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 17;26(10):107957.
doi: 10.1016/j.isci.2023.107957. eCollection 2023 Oct 20.

Sex-related incidence and survival differences in pediatric high-grade glioma subtypes: A population-based cohort study

Raoull Hoogendijk  1 , Jasper van der Lugt  1 , Josh Baugh  1 , Cassie Kline  2 , Mariette Kranendonk  1 , Eelco Hoving  1   3 , Leontien Kremer  1   4 , Pieter Wesseling  1   5 , Henrike Karim-Kos  1   6 , Dannis van Vuurden  1
Affiliations

Sex-related incidence and survival differences in pediatric high-grade glioma subtypes: A population-based cohort study

Raoull Hoogendijk et al. iScience. .

Abstract

Not much is known on sex differences in incidence, survival, and treatment characteristics for midline and hemispheric pHGGs. This population-based study confirms previously reported study results that found worse survival outcomes for malignant diffuse gliomas in girls in the age group 0-9 years. Additionally, in our study we pinpoint this difference to girls with midline pHGGs aged 0-4 years. We provide insight in the possible underlying mechanisms contributing to sex survival differences in pHGG patients. With first line treatment having no impact on the higher risk of dying for girls, but age and tumor characteristics having a neutralizing effect. The results of this population-based study serve as a basis for future pre-clinical and clinical studies to further unravel the underlying mechanisms responsible for the survival gap between sexes in midline pHGG.

Keywords: Cancer; Pediatrics; Population; Public health.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Incidence rates for pediatric high-grade gliomas (pHGGs) Average incidence rate per million person-years for (A) midline and (B) hemispheric pediatric high-grade gliomas (pHGGs) stratified to sex and age.
Figure 2
Figure 2
Progression Free Survival (PFS) and Overall Survival (OS) for pediatric high-grade gliomas (pHGGs) (A) pHGG OS and PFS. (B) pHGG OS stratified to midline pHGG and hemispheric pHGG. (C) Midline pHGG OS and PFS. (D) Midline pHGG OS stratified to boys and girls. (E) Hemispheric pHGG OS and PFS. (F) Hemisphiric pHGG OS stratified to boys and girls.
See this image and copyright information in PMC

References

    1. Fischer C., Petriccione M., Donzelli M., Pottenger E. Improving Care in Pediatric Neuro-oncology Patients: An Overview of the Unique Needs of Children With Brain Tumors. J. Child Neurol. 2016;31:488–505. doi: 10.1177/0883073815597756. - DOI - PMC - PubMed
    1. Jones C., Karajannis M.A., Jones D.T.W., Kieran M.W., Monje M., Baker S.J., Becher O.J., Cho Y.J., Gupta N., Hawkins C., et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2017;19:153–161. doi: 10.1093/neuonc/now101. - DOI - PMC - PubMed
    1. Hoogendijk R., van der Lugt J., van Vuurden D., Kremer L., Wesseling P., Hoving E., Karim-Kos H.E. Survival rates of children and young adolescents with CNS tumors improved in the Netherlands since 1990: A population-based study. Neurooncol. Adv. 2022;4:vdab183. doi: 10.1093/noajnl/vdab183. - DOI - PMC - PubMed
    1. Walker D.A., Liu J., Kieran M., Jabado N., Picton S., Packer R., St Rose C., CPN Paris 2011 Conference Consensus Group A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol. 2013;15:462–468. doi: 10.1093/neuonc/nos330. - DOI - PMC - PubMed
    1. Cohen K.J., Pollack I.F., Zhou T., Buxton A., Holmes E.J., Burger P.C., Brat D.J., Rosenblum M.K., Hamilton R.L., Lavey R.S., Heideman R.L. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011;13:317–323. doi: 10.1093/neuonc/noq191. - DOI - PMC - PubMed

LinkOut - more resources